Biotech News
Related news
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-05-06 20:01 EST
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
CVRXCVRx2026-07-23 20:30 EST
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
MLYSMineralys Therapeutics2026-08-04 12:00 EST
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
ALTAltimmune2026-08-05 12:00 EST
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
BLTEBelite Bio2026-08-06 12:00 EST
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
RYTMRhythm Pharmaceuticals2026-07-21 12:00 EST
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
VANIVivani Medical2026-08-13 20:05 EST
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
BLTEBelite Bio2026-08-13 01:45 EST
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
Stock data
- Close
- 3.54 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States